| Debra Young, MED,OTR/L,SCEM,ATP | |
|
107 Syracuse Dr, Newark, DE 19713-8101 | |
| (302) 981-3362 | |
| Not Available |
| Full Name | Debra Young |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist - Environmental Modification |
| Location | 107 Syracuse Dr, Newark, Delaware |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518093970 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Debra Young, MED,OTR/L,SCEM,ATP 107 Syracuse Dr, Newark, DE 19713-8101 Ph: (302) 981-3362 | Debra Young, MED,OTR/L,SCEM,ATP 107 Syracuse Dr, Newark, DE 19713-8101 Ph: (302) 981-3362 |
News Archive
Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.
Nearly 90 percent of patients at long-term care facilities don't take advantage of dental services, even when they are free, a recent study by University at Buffalo researchers has found.
Today, the Center for Consumer Freedom (CCF) is running a full-page ad in the New York Times, continuing its million dollar ad campaign against the New York City Department of Health's hyperbolic "Don't drink yourself fat" PSA campaign. The Center will also continue to run ads in the New York Daily News and New York Post that ask New Yorkers, "What's Next?" and "Big Apple or Big Brother?"
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) determined by a vote of 11-0 with 1 abstention that, in patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent (IMiD), the benefit-risk assessment is favorable for the use of Kyprolis.
› Verified 2 days ago
Mara L Sharp, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 Tyre Ave, Newark, DE 19711 Phone: 302-454-2047 Fax: 302-454-5442 | |
Elizabeth B Jones, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 Tyre Ave, Newark, DE 19711 Phone: 302-454-2047 Fax: 302-454-5443 | |
Stephanie Vantrease, MS OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 620 E Chestnut Hill Rd, Newark, DE 19713 Phone: 302-985-3281 | |
Ellen Erin Latronico, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 Tyre Ave, Newark, DE 19711 Phone: 302-454-2047 Fax: 302-454-5442 | |
Samantha Fulton, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 99 Middleboro Rd, Newark, DE 19711 Phone: 302-992-5574 | |
Warna Warren, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 Tyre Ave, Newark, DE 19711 Phone: 302-454-2047 | |
Mrs. Gina Castiglione-jeandell, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 212 Arrowwood Dr, Newark, DE 19713 Phone: 302-379-4329 |